Skip to main content

TreatPolyQ – Industrial Academic Initial Training Network towards treatment of Polyglutamine Diseases

Objective

Protein aggregation is a hallmark of many late onset neurodegenerative disorders including Parkinson’s Disease (PD), Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS), prion diseases as well as the group of polyglutamine diseases (polyQ). The aim of this proposal is to create a network of European partners bridging important basic mechanisms involved in proteinopathies, research of model diseases and treatment approaches. The “TreatPolyQ” network will focus on two main representatives of the polyQ diseases: Huntington’s disease as the most common polyQ disease as well as spinocerebellar ataxia type 3 (SCA3) as the most frequent autosomal-dominantly inherited ataxia. Patients suffer from a multitude of neurological symptoms including movement abnormalities with late onset and in a progressive manner. Up to now, no treatment or cure is available. The network will be consisting of a rare combination of experts from basic and translational research, including a Nobel prize laureate, four industrial partners (two medium, and two small companies, all incorporated as full participants) and academic leaders of the field. The network not only focuses on one special aspect of a disease but spans several important disease-associated mechanism as well as promising treatment strategies for HD and SCA3 (protein transport, protein folding, protein degradation via both the ubiquitin-proteasome system and autophagy), likely to be important across a range of neurodegenerative diseases. In order to implement these research projects, extensive collaborations and temporarily personnel secondments of the involved researchers will take place, enhancing interdisciplinary transfer of knowledge. Beyond the personalized local training plan for each employed researcher within the Network, there will be 4 structured courses covering aspects ranging from structural biology to protein degradation to model organisms and drug development, including soft skill training.

Field of science

  • /natural sciences/biological sciences/molecular biology/structural biology
  • /medical and health sciences/basic medicine/neurology/amyotrophic lateral sclerosis
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/protein folding

Call for proposal

FP7-PEOPLE-2010-ITN
See other projects for this call

Funding Scheme

MC-ITN - Networks for Initial Training (ITN)

Coordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Address
Geschwister-scholl-platz
72074 Tuebingen
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 533 510
Administrative Contact
Holm Graessner (Dr.)

Participants (15)

Klinik Max Planck Institut für Psychiatrie
Germany
EU contribution
€ 222 015
Address
Hofgartenstrasse 8
80539 Muenchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Manfred Messerschmidt (Mr.)
INSTITUT CURIE
France
EU contribution
€ 246 392
Address
Rue D'ulm 26
75231 Paris
Activity type
Research Organisations
Administrative Contact
Corinne Cumin (Ms.)
ENKAM PHARMACEUTICALS A/S

Participation ended

Denmark
Address
Fruebjergvej, 3
2100 Copenhagen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Morten Albrechtsen (Mr.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 246 099
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Riitta Ljungström (Ms.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 246 392
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Michele Saumon (Ms.)
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Israel
EU contribution
€ 251 385
Address
Senate Building Technion City
32000 Haifa
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mark Davison (Mr.)
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 261 223
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Cann (Mr.)
AC IMMUNE SA
Switzerland
EU contribution
€ 238 461
Address
Parc Scientifique Epfl, Pse B
1015 Lausanne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jean-Fabien Monin (Mr.)
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO
Portugal
EU contribution
€ 211 441
Address
Universidade De Coimbra Largo Marques De Pombal
3004 517 Coimbra
Activity type
Research Organisations
Administrative Contact
Silvia Sousa (Ms.)
KING'S COLLEGE LONDON
United Kingdom
EU contribution
€ 261 223
Address
Strand
WC2R 2LS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Paul Labbett (Mr.)
SIENA BIOTECH SPA
Italy
EU contribution
€ 240 518
Address
Via Fiorentina 1
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laura Lucaroni (Dr.)
H. LUNDBECK AS
Denmark
EU contribution
€ 281 488
Address
Ottiliavej 7-9
2500 Valby
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Karina Fog (Dr.)
UNIVERSITE PARIS DIDEROT - PARIS 7
France
EU contribution
€ 257 129
Address
Rue Thomas Mann 5
75205 Paris
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Muriel Maurice (Ms.)
MAX IV Laboratory, Lund University
Sweden
EU contribution
€ 260 042
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pia Berntsson (Dr.)
NSGENE AS

Participation ended

Denmark
Address
Baltorpvej 154
2750 Ballerup
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Lars Wahlberg (Dr.)